| Abstract |
【Abstract】Objective investigate the risk factors for extra pyramidal symptoms (EPS) in the treatment of schizophrenia with aripiprazole. Methods 80 patients with schizophrenia were selected and treated with aripiprazole monotherapy. The total effective rate and the total incidence of adverse reactions were observed. Patients were divided into EPS group and non-EPS group according to whether the patient during the treatment of EPS. The gender, age, course of disease, the BMI of before and after treatment, the PANSS baseline score, the increase rate of dose, the minimum dose, the maximum dose were compared between two groups. Parallel multivariate linear regression analysis was made to explore the risk factors for aripiprazole after treatment of schizophrenia. Results The PANSS score of 76 patients before treatment was (83.6±7.6) points and decreased to (41.6 ± 5.2)points, the difference was statistically significant (P<0.05). The total effective rate was 82.3%(63/76), and there was no significant difference in the total effective rate of patients with different severity (P> 0.05). The incidence of adverse events was 28.9% (22/76), and the incidence of EPS was 15.8% (12/76). There were no significant difference in gender, age, course of disease and the BMI of before and after treatment between EPS group and non-EPS group (P> 0.05). The PANSS baseline score, increase rate of dose, the minimum dose and the maximum dose of EPS group were significantly higher than those in the non-EPS group (P<0.05). The PANSS baseline score, the increase rate of dose, the maximum dose of aripiprazole were the risk factors in the treatment of schizophrenia (P<0.05). Conclusion Aripiprazole is effective in the treatment of schizophrenia. The PANSS baseline score, the increase rate of dose and the maximum dose of aripiprazole were the risk factors of EPS in the treatment of schizophrenia , it is worth attention.
|